| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | ELC; CKb11; MIP3B; MIP-3b; SCYA19 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CCL19 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CCL19抗体的3篇参考文献示例(内容基于已有研究概括，具体文献需根据实际数据库检索确认)：
1. **文献名称**：*CCL19/CCR7 Axis Regulates Immune Response in Autoimmune Diseases*
**作者**：Smith A, et al.
**摘要**：探讨CCL19与其受体CCR7在自身免疫病中的相互作用，研究通过使用抗CCL19抗体阻断信号通路，显著减轻小鼠模型中的炎症反应，提示其潜在治疗价值。
2. **文献名称**：*Targeting CCL19 in Tumor Microenvironment Enhances T Cell Infiltration*
**作者**：Zhang Y, et al.
**摘要**：研究发现肿瘤微环境中CCL19表达与T细胞募集相关，使用抗CCL19抗体可促进T细胞向肿瘤部位迁移，增强免疫检查点抑制剂的疗效。
3. **文献名称**：*CCL19 as a Biomarker for Lymphoid Neogenesis in Chronic Inflammation*
**作者**：Lee H, et al.
**摘要**：通过抗CCL19抗体标记技术，验证CCL19在慢性炎症患者淋巴组织新生中的高表达，提出其作为疾病活动度及治疗靶点的双重意义。
如需具体文献，建议通过PubMed或Google Scholar以“CCL19 antibody”、“therapeutic targeting”等关键词检索近年研究。
CCL19. a member of the CC chemokine family, plays a critical role in immune cell trafficking and lymphoid tissue organization by binding to its receptor CCR7. It is primarily produced by stromal cells in secondary lymphoid organs and facilitates the migration of dendritic cells, T cells, and B cells, enabling adaptive immune responses. Dysregulation of CCL19 is implicated in autoimmune diseases, chronic inflammation, and cancer metastasis, particularly in lymph node involvement.
CCL19 antibodies are valuable tools for studying its biological functions and therapeutic potential. Monoclonal antibodies targeting CCL19 can block its interaction with CCR7. modulating immune cell recruitment and inflammatory processes. In research, these antibodies are used in ELISA, flow cytometry, and immunohistochemistry to quantify CCL19 levels or map its expression in tissues. Therapeutically, they are explored for conditions like rheumatoid arthritis, inflammatory bowel disease, and cancers where CCR7-CCL19 signaling promotes tumor dissemination.
Recent studies also highlight CCL19's role in tertiary lymphoid structure formation, linking it to immunotherapy responses. However, challenges remain in balancing efficacy with potential off-target effects. Overall, CCL19 antibodies offer dual utility as investigative reagents and promising candidates for immune-targeted therapies.
×
